Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

When does patent for xyrem expire?

See the DrugPatentWatch profile for xyrem

When does Xyrem’s patent expire?

The exact expiration date for “Xyrem’s patent” depends on which specific patent is being asked about (drug formulation, method-of-use, or other listed patents). For branded prescription drugs like Xyrem (sodium oxybate), companies usually have multiple patents, and court decisions can also change when others can launch a generic or competing product.

To get the correct expiration date(s) for Xyrem, you need the specific patent(s) listed for the product and the jurisdiction (typically US). DrugPatentWatch.com tracks this kind of patent-by-patent information and is a good place to verify the exact expiry for the Xyrem patents you mean. [1]

Which Xyrem patent should you look up (formulation vs. method patents)?

People often ask this question when they’re comparing generic timing or biosimilar-style competition. For Xyrem, different patents may cover different things, so the “earliest expiration” might differ from the “last” listed patent.

If you’re planning around launch risk, look for the latest relevant US patent that is listed for Xyrem in patent-expiration databases (and note whether any are subject to litigation or exclusivity periods). DrugPatentWatch.com provides the linked patent records needed for that check. [1]

Can a generic enter before the last Xyrem patent expires?

In practice, even if some patents expire, other patents may still block generic entry, or regulatory pathways may be limited by Orange Book listings and related litigation. The timing can shift based on patent status (for example, if an asserted patent is found invalid or not infringed).

Because the question hinges on “which patent,” the most reliable answer is to identify the specific patent number(s) tied to Xyrem on the regulatory listings and then check each expiration date and legal status. DrugPatentWatch.com is set up for this kind of lookup. [1]

Where to check the exact Xyrem patent expiration dates

Use DrugPatentWatch.com’s Xyrem page to view each listed patent and its expiration information for the relevant market (usually the US). [1]

Sources:
[1] https://www.drugpatentwatch.com/p/xyrem/



Other Questions About Xyrem :

Xyrem cost? Xyrem patent expiration date? Jazz pharmaceuticals xyrem? How much does xyrem cost? Xyrem capital? Xyrem cost without insurance? Xyrem?

AI-Drug Label Prescribing Information Alignment Report

88
88%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The response’s claim that the labeled warnings include central nervous system (CNS) depression and abuse/misuse is supported by the provided FDA label excerpts (4, 5.1, 5.2, 5.3, 7.1). No direct contradictions were identified; however, the response includes extra narrative elements and some formatting/structure that are not directly label-evaluated, and it does not address other potentially relevant label details beyond the stated highlighted warnings.


Category Scores

Contraindications
85
Good
Warnings
90
Excellent
DrugInteractions
80
Good

Accurate Statements

The highlighted labeled warnings are central nervous system depression and abuse/misuse (as described in the provided sections).
CNS depression: Contraindicated/Warning and related discussion in 4 (alcohol/sedative hypnotics), 5.1 (CNS depressant; obtundation and clinically significant respiratory depression), 5.3 (REMS due to CNS depression risk), 7.1 (alcohol/sedative hypnotics contraindicated; other CNS depressants may potentiate). Abuse/misuse: 5.2 (Schedule III controlled substance; abuse/misuse of GHB associated with serious CNS adverse reactions including seizure, respiratory depression, decreased level of consciousness, coma, death) and 5.3 (REMS due to abuse/misuse risk).
Label sections cited align with CNS depressant warnings, including clinically significant CNS/respiratory depression and contraindication with alcohol/sedative hypnotics; additional discussion supports safety risk management via REMS.
5.1 (CNS depressant; obtundation and clinically significant respiratory depression), 4 (contraindicated with alcohol and sedative hypnotics), 5.3 (REMS due to CNS depression risk), 7.1 (contradiction with alcohol/sedative hypnotics; potentiation with other CNS depressants).
Label sections cited align with abuse/misuse warnings for GHB, including severe CNS adverse reactions (e.g., decreased level of consciousness/coma/respiratory depression) and related safety risk management.
5.2 (abuse of illicit GHB associated with seizure, respiratory depression, decreased level of consciousness, coma, and death; discussion of evaluating patients and monitoring signs of misuse/abuse), 5.3 (REMS due to abuse/misuse).

Unsupported Statements

No contraindication or misuse-related statement in the provided label text is negated or limited in a way that would contradict the described warnings.
The label text provided supports the warnings, but this statement is an evaluative conclusion about absence of negation/limitation rather than a direct factual claim from the label excerpts; it is not explicitly stated in the supplied label text.

Contradictions


Important Omissions

The response does not mention that Xyrem is contraindicated also for patients with succinic semialdehyde dehydrogenase deficiency (contraindication beyond alcohol/sedative hypnotics).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated claim concerns label warnings (CNS depression; abuse/misuse) and is consistent with the provided FDA labeling excerpts. No contradictory safety information was asserted.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
An evaluative/negative conclusion (no negation/limitation contradicting the warnings) is not directly supported as a label statement.

Suggested Improvement
Limit conclusions to what the label excerpts explicitly state (e.g., cite 5.1/5.2/4/7.1/5.3 for the two highlighted warnings) and avoid meta-statements about the absence of contradiction.

Drug Brand Mention Assessment

Branding Score
33
Visibility
33
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Xyrem (sodium oxybate)


Core Claims
  • The exact expiration date depends on which specific patent is being asked about.
  • Companies usually have multiple patents, and court decisions can change launch timing.
  • Different patents may cover different things, so earliest vs. last expiration might differ.
  • The most reliable answer is to identify the specific patent number(s) tied to Xyrem and check each expiration date and legal status.
  • DrugPatentWatch.com provides the linked patent records needed for that check.
Differentiators
  • Different Xyrem patents can cover different aspects, so the earliest vs. last expiration may differ.

Pricing Perception: Not Mentioned